Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease

Acta Pharmacologica Sinica

Volumn 35, Issue 8, 2014, Pages 1074-1081

  Yu, Ye ^a   Jing, Jing Feng ^a   Tong, Xian Kun ^a   He, Pei Lan ^a   Li, Yuan Chao ^a   Hu, You Hong ^a   Tang, Wei ^a   Zuo, Jian Ping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

2,4 diaminoquinazoline; Carboxamide; Hepatitis C virus; NS3 4A protease; Secreted embryonic alkaline phosphatase (Seap); Telaprevir

Indexed keywords

2,4 DIAMINOQUINAZOLINE DERIVATIVE; ALKALINE PHOSPHATASE; AMIDE; ANTIVIRUS AGENT; HZ 1157; LZ 110618 6; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE; TELAPREVIR; UNCLASSIFIED DRUG; 2,4-DIAMINOQUINAZOLINE; NS3 PROTEIN, HEPATITIS C VIRUS; QUINAZOLINE DERIVATIVE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; DRUG STRUCTURE; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUH 7.5.1 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; LUCIFERASE ASSAY; PLASMID; REPLICON; REPORTER GENE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HEPACIVIRUS; HEPATITIS C; METABOLISM; VIROLOGY;

AMIDES; ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HEPACIVIRUS; HEPATITIS C; HUMANS; QUINAZOLINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84905667998     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.55     Document Type: Article

References (31)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet infect Dis 2005; 5: 558-67.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81.
3. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. J Gastroenterol 2007; 42: 411-23.
4. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9.
8. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
9. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
10. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
11. Hsu CS. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369: 678.
12. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
13. Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 268-76.
14. Yang L, Shi LP, Chen HJ, Tong XK, Wang GF, Zhang YM, et al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin 2014; 35: 410-8.
15. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
16. Chao B, Tong XK, Tang W, Li DW, He PL, Garcia JM, et al. Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors. J Med Chem 2012; 55: 3135-43.
17. Shi JJ, Ji FH, He PL, Yang YX, Tang W, Zuo JP, et al. Synthesis and hepatitis C antiviral activity of 1-aminobenzyl-1H-indazole-3- carboxamide analogues. ChemMedChem 2013; 8: 722-5.
18. Han Q, Xu C, Wu C, Zhu W, Yang R, Chen X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res 2009; 145: 63-73.
19. Shi JJ, Ji FH, He PL, Yang YX, Tang W, Zuo JP, et al. Synthesis and hepatitis C antiviral activity of 1-aminobenzyl-1H-indazole-3- carboxamide analogues. ChemMedChem 2013; 8: 722-5.
20. Tong XK, Qiu H, Zhang X, Shi LP, Wang GF, Ji FH, et al. WSS45, a sulfated alpha-D-glucan, strongly interferes with Dengue 2 virus infection in vitro. Acta Pharmacol Sin 2010; 31: 585-92.
21. He SJ, Lin ZM, Wu YW, Bai BX, Yang XQ, He PL, et al. Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZBxNZW F1 mice via interference with TLR-mediated APC response. Acta Pharmacol Sin 2013; 35: 219-29.
22. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50: 899-909.
23. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
24. Ye L, Li J, Zhang T, Wang X, Wang Y, Zhou Y, et al. Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells. Virus Res 2012; 168: 33-40.
25. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
26. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294-9.
27. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
28. Saito T, Gale M Jr. Regulation of innate immunity against hepatitis C virus infection. Hepatol Res 2008; 38: 115-22.
29. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 1994; 68: 5045-55.
30. Failla C, Tomei L, De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 1994; 68: 3753-60.
31. Bianchi E, Steinkuhler C, Taliani M, Urbani A, Francesco RD, Pessi A. Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease. Anal Biochem 1996; 237: 239-44.